相关临床试验
423
54 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1989
进行中（未招募）
28
6.6%
已完成
228
53.9%
No Longer Available
3
0.7%
尚未招募
26
6.2%
招募中
76
18.0%
暂停
2
0.5%
终止
39
9.2%
撤回
21
5.0%
暂无批准数据
- UNC Lineberger Comprehensive Cancer Center has received a $40 million grant from the OpenAI Foundation to generate data aimed at making personalized cancer vaccines more effective. - The funding supports AI-based selection of tumor antigens and parallel clinical trials comparing vaccine formulations in triple-negative breast cancer. - The grant coincides with the launch of the OpenAI Foundation's Public Data for Health program, which backs open-access datasets for life science research. - Researchers say many personalized cancer vaccines fail in development because antigen selection remains too arbitrary, limiting clinical efficacy.
- Weekly electronic symptom check-ins significantly improved symptom control and physical function in patients with advanced cancer, with the greatest benefits seen among historically underserved groups including Black patients and those with lower educational attainment. - The PRO-TECT trial enrolled 1,191 adults across 52 U.S. community oncology clinics, finding that remote monitoring bridged communication gaps rather than exacerbating health disparities. - Black patients using the system reported feeling more in control of their care, with 61% strongly agreeing that home symptom reporting improved their sense of agency compared to 42% of white patients. - The intervention reduced emergency department visits overall, and a national initiative called OncoPRO has been launched in partnership with ASCO and the American Cancer Society to implement remote symptom monitoring in routine practice.
- UNC Lineberger Comprehensive Cancer Center launches hybrid decentralized trials with $250,000 federal funding to serve North Carolina's 33% rural population, reducing travel barriers to Chapel Hill. - City of Hope introduces a national clinical trials model operating through a centralized hub across 37 locations, enabling simultaneous trial openings across multiple states. - Both initiatives demonstrate early success with improved patient enrollment and retention, addressing geographic disparities in cancer clinical trial access. - The models focus on bringing experimental treatments closer to patients' homes while maintaining specialized care coordination and reducing administrative burdens on participating hospitals.
- The US oncology enterprise faces simultaneous threats from proposed NCI budget cuts that could reduce R01 grant funding to just the fourth to fifth percentile, down from the historically disappointing 10th percentile. - Dramatic alterations to the NCI Cancer Centers program and peer review process are causing widespread alarm at institutions responsible for deploying 75% or more of national cancer research funding. - Proposed changes to Medicare, Medicaid, and the 340B Drug Discount Program threaten clinical care delivery and could force substitution of consistent management with emergency services. - The financial instability poses significant risks to the future talent pipeline in academic oncology, potentially undermining 50 years of national investment in cancer research infrastructure.
- The UNC Lineberger Comprehensive Cancer Center received $28 million from ARPA-H to develop EVOLVE, an innovative clinical trial that adapts metastatic breast cancer treatment in real-time based on tumor changes. - The trial will enroll up to 700 patients and use biomarkers, including circulating tumor DNA, to detect treatment resistance early and modify therapy before symptoms return. - EVOLVE represents a paradigm shift from traditional clinical trials by continuously monitoring tumor evolution and matching patients to the most promising therapies as their cancer changes. - The collaborative effort involves 15 institutions across the Translational Breast Cancer Research Consortium, addressing the critical need for curative therapies in metastatic breast cancer where only one in three patients survive beyond five years.
- Continuity Biosciences has acquired Focal Medical, a North Carolina-based company developing site-specific chemotherapy using iontophoresis technology for pancreatic cancer treatment. - Focal Medical's lead product candidate uses an iontophoresis device to deliver gemcitabine directly to pancreatic tumors, which has received FDA IND clearance with Phase 1b trials expected to begin later this year. - The acquisition includes Focal Medical's patent estate, technology platform, and a dedicated R&D facility in Cary, NC, positioning Continuity as a leader in device-targeted therapeutics for solid tumors. - The iontophoresis approach enhances local drug concentration while minimizing systemic toxicity, addressing key limitations of traditional gemcitabine administration in pancreatic cancer.
- CAR T-cell therapy and bispecific antibodies have transformed hematologic malignancy treatment, offering new hope beyond traditional chemotherapy and targeted drugs. - Real-world data indicates concerning disparities, with Black patients showing inferior progression-free survival and Hispanic patients experiencing slightly worse overall survival rates. - These advanced cellular therapies present unique challenges, requiring specialized healthcare centers and careful management of toxicities including cytokine release syndrome and B-cell depletion.
- AYA cancer programs address the unique challenges faced by adolescents and young adults (ages 15-39) diagnosed with cancer, offering tailored support. - A UNC Lineberger program significantly increased AYA access to fertility counseling, clinical trial enrollment, and guideline-recommended care. - NCI is funding studies leveraging technology to address cost issues and expand access to AYA programs, including web-based resources for coping with distress. - Addressing financial help, fertility preservation, and school/career issues are consistently the most common areas of need and assistance.
• Ifinatamab deruxtecan (I-DXd) demonstrated promising activity in patients with extensive-stage small cell lung cancer (ES-SCLC) at the World Congress on Lung Cancer. • The antibody-drug conjugate (ADC) I-DXd showed a dose-response relationship, with higher doses yielding improved overall response rates in ES-SCLC. • Combination strategies involving ADCs like I-DXd with immunotherapy are being explored due to the potential for immunogenic cell death induction. • Protein engineering advancements are enabling the development of targeted therapies with improved clinical responses in lung cancer.
- The addition of Versamune HPV (PDS0101) to pembrolizumab demonstrated robust and durable responses in first-line treatment for HPV16-positive recurrent or metastatic HNSCC. - In the VERSATILE-002 trial, the combination therapy achieved a median overall survival of 30 months and an objective response rate of 35.8% in patients with a CPS ≥ 1. - The safety profile of the combination was consistent with pembrolizumab alone, with mostly mild injection site reactions, supporting its continued evaluation. - A phase 3 trial (VERSATILE-003) is being planned to compare the combination with pembrolizumab monotherapy to validate the regimen's efficacy and safety.
